Analyst Reco. Axonics, Inc.

Equities

AXNX

US05465P1012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-12 pm EDT			5-day change	1st Jan Change
67 ^USD	0.00%		+0.21%	+7.67%

May. 16	Axonics Implant Approved in Australia to Treat Overactive Bladders	MT
May. 16	Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Needham Downgrades Axonics to Hold From Buy	Jan. 17	MT
Truist Securities Downgrades Axonics to Hold From Buy, Adjusts Price Target to $71 From $73	Jan. 12	MT
CL King Downgrades Axonics to Neutral From Buy	Jan. 12	MT
Leerink Partners Downgrades Axonics to Market Perform From Outperform, Sets Price Target at $71	Jan. 12	MT
Piper Sandler Downgrades Axonics to Neutral From Overweight, Cuts Price Target to $71 From $75	Jan. 12	MT
Wells Fargo Downgrades Axonics to Equalweight From Overweight, Raises Price Target to $71 From $68	Jan. 10	MT
Nephron Research Downgrades Axonics to Hold From Buy, Raises Price Target to $71 From $65	Jan. 09	MT
Wolfe Research Downgrades Axonics to Peer Perform From Outperform	Jan. 09	MT
RBC Lifts Price Target on Boston Scientific to $67 From $61, Cites Stock Runup, Growth Opportunities Amid Axonics Deal, Outperform Kept	Jan. 09	MT
RBC Downgrades Axonics to Sector Perform From Outperform, Raises Price Target to $71 From $69 Amid Boston Scientific Deal	Jan. 09	MT
Investors lower their expectations	Jan. 08
Needham Adjusts Price Target on Axonics to $63 From $76, Maintains Buy Rating	23-10-31	MT
Morgan Stanley Cuts Price Target on Axonics to $69 From $76, Keeps Overweight Rating	23-10-31	MT
Baird Adjusts Price Target on Axonics to $70 From $69, Maintains Outperform Rating	23-07-28	MT
Needham Adjusts Price Target on Axonics to $76 From $73, Maintains Buy Rating	23-07-28	MT
KeyBanc Initiates Axonics at Overweight With $70 Price Target, Confident in Ability to Meet or Exceed Consensus Growth Views	23-07-13	MT
RBC Cuts Price Target on Axonics to $75 From $85, Maintains Outperform Rating	23-07-12	MT
CL King Starts Axonics at Buy With $75 Price Target	23-05-23	MT
Needham Adjusts Price Target on Axonics to $73 From $71, Maintains Buy Rating	23-05-02	MT
Truist Securities Adjusts Price Target on Axonics to $73 From $82, Maintains Buy Rating	23-04-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Axonics, Inc.

Equities

AXNX

US05465P1012

Analyst Reco.

Filters